Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALDX |
---|---|---|
09:32 ET | 9749 | 5.13 |
09:33 ET | 900 | 5.06 |
09:35 ET | 14250 | 4.97 |
09:37 ET | 6284 | 4.95 |
09:39 ET | 4864 | 4.9304 |
09:42 ET | 1617 | 4.96 |
09:44 ET | 2900 | 4.975 |
09:46 ET | 2773 | 5 |
09:48 ET | 5898 | 5.01 |
09:50 ET | 566 | 5 |
09:51 ET | 3077 | 5 |
09:53 ET | 1509 | 5.005 |
09:55 ET | 449 | 5.015 |
10:02 ET | 5494 | 5.01 |
10:04 ET | 11765 | 5.06 |
10:06 ET | 3700 | 5.08 |
10:08 ET | 100 | 5.07 |
10:09 ET | 400 | 5.08 |
10:11 ET | 1799 | 5.1 |
10:13 ET | 600 | 5.11 |
10:18 ET | 200 | 5.1 |
10:20 ET | 1826 | 5.08 |
10:22 ET | 300 | 5.065 |
10:24 ET | 5475 | 5.045 |
10:27 ET | 1358 | 5.07 |
10:29 ET | 11988 | 5.11 |
10:31 ET | 400 | 5.11 |
10:33 ET | 200 | 5.12 |
10:36 ET | 200 | 5.1 |
10:42 ET | 251 | 5.1 |
10:44 ET | 600 | 5.08 |
10:45 ET | 1817 | 5.13 |
10:47 ET | 7247 | 5.1699 |
10:49 ET | 196 | 5.17 |
10:51 ET | 100 | 5.18 |
11:02 ET | 300 | 5.1984 |
11:03 ET | 2061 | 5.19 |
11:05 ET | 100 | 5.195 |
11:07 ET | 2718 | 5.2199 |
11:12 ET | 927 | 5.18 |
11:23 ET | 6442 | 5.1915 |
11:25 ET | 400 | 5.19 |
11:34 ET | 900 | 5.19 |
11:36 ET | 4100 | 5.2 |
11:38 ET | 455 | 5.22 |
11:39 ET | 212 | 5.23 |
11:43 ET | 800 | 5.21 |
11:50 ET | 500 | 5.2 |
11:52 ET | 1200 | 5.21 |
11:54 ET | 1000 | 5.23 |
11:57 ET | 100 | 5.22 |
12:01 ET | 1636 | 5.21 |
12:03 ET | 121 | 5.21 |
12:08 ET | 300 | 5.19 |
12:10 ET | 20858 | 5.121 |
12:12 ET | 100 | 5.16 |
12:14 ET | 941 | 5.1833 |
12:17 ET | 1528 | 5.19 |
12:26 ET | 102 | 5.1801 |
12:32 ET | 12544 | 5.1403 |
12:33 ET | 100 | 5.145 |
12:37 ET | 1548 | 5.15 |
12:39 ET | 997 | 5.1531 |
12:42 ET | 100 | 5.18 |
12:46 ET | 400 | 5.1507 |
12:48 ET | 400 | 5.16 |
12:53 ET | 100 | 5.17 |
12:55 ET | 100 | 5.16 |
12:57 ET | 245 | 5.16 |
01:02 ET | 200 | 5.17 |
01:04 ET | 642 | 5.17 |
01:11 ET | 245 | 5.17 |
01:15 ET | 400 | 5.1799 |
01:20 ET | 100 | 5.18 |
01:22 ET | 141 | 5.175 |
01:24 ET | 438 | 5.18 |
01:26 ET | 100 | 5.2 |
01:31 ET | 1079 | 5.18 |
01:33 ET | 277 | 5.175 |
01:36 ET | 100 | 5.175 |
01:38 ET | 2100 | 5.18 |
01:40 ET | 100 | 5.1802 |
01:42 ET | 5213 | 5.19 |
01:44 ET | 1244 | 5.19 |
01:45 ET | 300 | 5.21 |
01:51 ET | 962 | 5.2009 |
01:54 ET | 599 | 5.24 |
01:58 ET | 200 | 5.24 |
02:02 ET | 1200 | 5.24 |
02:03 ET | 859 | 5.2594 |
02:05 ET | 500 | 5.25 |
02:20 ET | 227 | 5.23 |
02:21 ET | 1348 | 5.205 |
02:25 ET | 1005 | 5.22 |
02:27 ET | 4980 | 5.22 |
02:32 ET | 100 | 5.23 |
02:38 ET | 100 | 5.22 |
02:39 ET | 100 | 5.22 |
02:41 ET | 2094 | 5.24 |
02:45 ET | 209 | 5.24 |
02:50 ET | 929 | 5.23 |
02:52 ET | 100 | 5.22 |
02:54 ET | 300 | 5.2203 |
02:56 ET | 100 | 5.22 |
02:57 ET | 400 | 5.21 |
02:59 ET | 1132 | 5.205 |
03:01 ET | 400 | 5.19 |
03:06 ET | 500 | 5.2 |
03:08 ET | 3368 | 5.22 |
03:15 ET | 255 | 5.235 |
03:17 ET | 1619 | 5.21 |
03:19 ET | 736 | 5.21 |
03:21 ET | 100 | 5.22 |
03:24 ET | 2094 | 5.23 |
03:28 ET | 210 | 5.245 |
03:30 ET | 3824 | 5.26 |
03:32 ET | 1184 | 5.25 |
03:35 ET | 303 | 5.24 |
03:39 ET | 800 | 5.235 |
03:42 ET | 2960 | 5.245 |
03:44 ET | 1700 | 5.225 |
03:46 ET | 700 | 5.23 |
03:50 ET | 100 | 5.24 |
03:51 ET | 2639 | 5.23 |
03:53 ET | 200 | 5.23 |
03:55 ET | 1096 | 5.25 |
03:57 ET | 10827 | 5.265 |
04:00 ET | 39047 | 5.27 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aldeyra Therapeutics Inc | 307.8M | -8.3x | --- |
Rezolute Inc | 304.2M | -4.1x | --- |
Design Therapeutics Inc | 301.2M | -6.2x | --- |
Compass Pathways PLC | 320.2M | -2.1x | --- |
Biomea Fusion Inc | 320.4M | -2.2x | --- |
Nautilus Biotechnology Inc | 322.7M | -4.7x | --- |
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $307.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -8.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.